Inotersen, sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis.

2024年8月13日 · Inotersen (brand name Tegsedi) is a self-administered, once-weekly injection that may be used to treat polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

2018年7月4日 · Inotersen (formerly IONIS-TTR Rx /ISIS 420915) is a 2′-O-methoxyethyl–modified antisense oligonucleotide inhibitor of the hepatic production of transthyretin protein.

2025年3月1日 · Inotersen injection is used to treat polyneuropathy (nerve disease) of hereditary transthyretin-mediated amyloidosis. This medicine is available only under a restricted distribution program called Tegsedi® REMS (Risk Evaluation and Mitigation Strategy) Program.

2024年10月29日 · Inotersen is an antisense oligonucleotide that targets the TTR protein, reducing TTR tissue deposition in patients with hATTR. Inotersen is a 2′-O-methoxyethyl-modified RNA molecule that binds TTR messenger ribonucleic acid (mRNA), inhibiting the expression of TTR protein via ribonuclease H (RNase H) degradation.

Inotersen (in oh TER sen) is used to treat nerve damage in patients with a certain genetic disorder called hereditary transthyretin-mediated amyloidosis (hATTR).

Tegsedi (Inotersen) is a chemically modified antisense oligonucleotide that inhibits the hepatic production of transthyretin (TTR). Several single-point mutations in TTR destabilize its structure, leading to the aggregation and accumulation of ...

Find patient medical information for inotersen subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Tegsedi ™ (inotersen) is a transthyretin-directed antisense oligonucleotide (ASO) inhibitor indicated for the treatment of adults with hereditary transthyretin amyloid polyneuropathy (ATTR-PN). It was developed by Ionis Pharmaceuticals and Akcea Therapeutics and first approved in the European Union in July 2018.

2025年1月7日 · Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It was FDA approved in October 2018.